# A shift in the cellular redox state redirects aspartate for export under glucose deprivation

**Authors:** Barbara Konrad, Gabriele Bluemel, Theresa Haitzmann, Tobias Frech, Anke Vandekeere, Mélanie Planque, Visnja Bubalo, Katharina Schindlmaier, Vanessa Jäger, Michael A. Dengler, Sarah Stryeck, Luka Brcic, Jörg Lindenmann, Philipp Stiegler, Doruntina Bresilla, Corina T. Madreiter-Sokolowski, Tobias Madl, Thomas O. Eichmann, Nikolaus Kneidinger, Sarah-Maria Fendt, Katharina Leithner

PMC · DOI: 10.1186/s40170-026-00420-x · Cancer & Metabolism · 2026-03-03

## TL;DR

Cancer and normal lung cells release more aspartate when glucose is scarce, due to changes in a key metabolic pathway.

## Contribution

The study reveals a novel metabolic adaptation involving aspartate export under glucose deprivation in lung cells.

## Key findings

- Low glucose increases aspartate synthesis and export in lung cancer and normal cells.
- Aspartate export is reduced under hypoxia and suppressed by knocking out GOT2.
- Restoring NADH reverses aspartate synthesis under low glucose conditions.

## Abstract

Glucose is an important fuel in cancer cells, however, its availability may be limited in solid tumors. Cell-autonomous, metabolic adaptations of cancer cells and non-malignant cells to glucose deprivation are still incompletely understood.

Here, we addressed the changes in central carbon metabolism in lung cancer cells and normal lung cells facing glucose limitation using stable isotopic labeling followed by nuclear magnetic resonance spectroscopy and mass spectrometry.

Elevated levels and the release of newly synthesized aspartate were among the most prominent changes in low compared to high glucose conditions. The low glucose-induced export of aspartate occurred in different lung cancer cell lines, but also bronchial epithelial cells and cancer-associated fibroblasts. It was accompanied by a reduced use of aspartate in purine synthesis and suppressed by hypoxia. A knockout of the malate-aspartate shuttle (MAS) enzyme mitochondrial aspartate aminotransferase (GOT2) decreased aspartate release. Low glucose conditions diminished reduced nicotinamide adenine dinucleotide (NADH) and restoring NADH reversed aspartate synthesis, suggesting that the distal, NADH-dependent arm of the MAS is compromised under glucose deprivation.

Cells accumulate and release aspartate, a biosynthetic precursor and signaling molecule, under low glucose conditions, largely due to a truncated MAS, as part of their adaptive metabolic response.

The online version contains supplementary material available at 10.1186/s40170-026-00420-x.

## Linked entities

- **Genes:** GOT2 (glutamic-oxaloacetic transaminase 2) [NCBI Gene 2806]
- **Chemicals:** aspartate (PubChem CID 5960), glucose (PubChem CID 5793), NADH (PubChem CID 439153)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** MDH1 (malate dehydrogenase 1) [NCBI Gene 4190] {aka DEE88, EIEE88, HEL-S-32, KAR, MDH-s, MDHA}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, SLC25A12 (solute carrier family 25 member 12) [NCBI Gene 8604] {aka AGC1, ARALAR, DEE39, EIEE39}, ME2 (malic enzyme 2) [NCBI Gene 4200] {aka ODS1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, SLC1A1 (solute carrier family 1 member 1) [NCBI Gene 6505] {aka DCBXA, EAAC1, EAAT3, SCZD18, hEAAC1}, SLC1A3 (solute carrier family 1 member 3) [NCBI Gene 6507] {aka EA6, EAAT1, GLAST, GLAST1}, SLC25A13 (solute carrier family 25 member 13) [NCBI Gene 10165] {aka ARALAR2, CITRIN, CTLN2, NICCD}, BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, TKT (transketolase) [NCBI Gene 7086] {aka HEL-S-48, HEL107, SDDHD, TK, TKT1}, MDH2 (malate dehydrogenase 2) [NCBI Gene 4191] {aka DEE51, EIEE51, M-MDH, MDH, MGC:3559, MOR1}, SLC25A11 (solute carrier family 25 member 11) [NCBI Gene 8402] {aka OGC, PGL6, PPGL6, SLC20A4}, PFKM (phosphofructokinase, muscle) [NCBI Gene 5213] {aka ATP-PFK, GSD7, PFK-1, PFK-A, PFK1, PFKA}, FBP1 (fructose-bisphosphatase 1) [NCBI Gene 2203] {aka FBP}, PCK2 (phosphoenolpyruvate carboxykinase 2, mitochondrial) [NCBI Gene 5106] {aka PEPCK, PEPCK-M, PEPCK2, mtPCK2}
- **Diseases:** solid (MESH:D018250), MAS (MESH:C564973), glucose (MESH:D018149), breast cancer (MESH:D001943), respiration (MESH:D012120), deficient (MESH:D007153), metastases (MESH:D009362), Hypoxia (MESH:D000860), non-small cell lung cancer (MESH:D002289), LUAD (MESH:D000077192), hypoxic (MESH:D002534), Cancer (MESH:D009369), lung cancer (MESH:D008175), PDAC (MESH:D010190)
- **Chemicals:** EDC (MESH:C024565), ice (MESH:D007053), Glucose (MESH:D005947), DHAP (MESH:D004099), PVDF (MESH:C024865), PBS (MESH:D007854), NAD (MESH:D009243), acetate (MESH:D000085), lysine (MESH:D008239), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (MESH:D005022), purine (MESH:C030985), MTBE (MESH:C043243), sucrose (MESH:D013395), GMP (MESH:C066524), chloroform (MESH:D002725), zirconium oxide (MESH:C028541), -glutamine (MESH:D005973), Citrate (MESH:D019343), CO2 (MESH:D002245), EGTA (MESH:D004533), ATP (MESH:D000255), AMP (MESH:D000249), Alexa Fluor 488 (MESH:C000711379), arginine (MESH:D001120), carbohydrate (MESH:D002241), purine nucleotide (MESH:D011685), MTBSTFA (MESH:C059151), serine (MESH:D012694), amine (MESH:D000588), R5P (MESH:C031626), amino acid (MESH:D000596), Fungizone (MESH:D000666), MOPS (MESH:C008550), OAA (MESH:D062907), Asp (MESH:D001224), pyridine (MESH:C023666), fructose-6-phosphate (MESH:C027618), glycerol-phosphate (MESH:D005994), helium (MESH:D006371), medronic acid (MESH:C027474), 2H (MESH:D003903), 13C5-glutamine (-), glycine (MESH:D005998), 13C (MESH:C000615229), NaOH (MESH:D012972), Malate (MESH:C030298), ribulose-5-phosphate (MESH:C031524), asparagine (MESH:D001216), HCl (MESH:D006851), glutamate (MESH:D018698), SDS (MESH:D012967), ACN (MESH:C084683), norvaline (MESH:C005313), xylulose-5-phosphate (MESH:C031625), DTAB (MESH:C022806), glutarate (MESH:D005977), EdU (MESH:C022811), acetyl-CoA (MESH:D000105), nucleotide (MESH:D009711), PEP (MESH:D010728)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** aspartate-glutamate, G6P, aspartate from glutamine, G011724N, aspartate to asparagine
- **Cell lines:** A549 lung cancer — Homo sapiens (Human), Lung squamous cell carcinoma, Cancer cell line (CVCL_3008), HCT-116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), H23 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1547), BEC — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_AR51)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955209/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12955209/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955209/full.md

---
Source: https://tomesphere.com/paper/PMC12955209